The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets.
Ito K, Nagata K, Ohta S, Matsuda Y, Ukai T, Yasuda I, Ota A, Kobayashi R, Kabata M, Sankoda N, Maeda T, Woltjen K, Yang L, Maruyama R, Katayama R, Yamamoto T, Yamada Y.
Ito K, et al. Among authors: nagata k.
Cell Rep. 2022 Apr 26;39(4):110721. doi: 10.1016/j.celrep.2022.110721.
Cell Rep. 2022.
PMID: 35476996
Free article.